Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives $12.40 Consensus Price Target from Brokerages

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have received a consensus rating of “Moderate Buy” from the five analysts that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $12.40.

Several equities analysts have weighed in on INO shares. HC Wainwright dropped their price objective on Inovio Pharmaceuticals from $5.00 to $3.00 and set a “neutral” rating on the stock in a research note on Monday, January 13th. Oppenheimer dropped their price target on shares of Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a research report on Monday, November 18th. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price objective on shares of Inovio Pharmaceuticals in a research report on Friday, January 10th. Finally, Royal Bank of Canada dropped their target price on shares of Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Friday, November 15th.

Inovio Pharmaceuticals Stock Down 2.0 %

INO stock opened at $1.92 on Tuesday. The firm has a market capitalization of $50.11 million, a PE ratio of -0.91 and a beta of 0.89. Inovio Pharmaceuticals has a twelve month low of $1.74 and a twelve month high of $14.75. The stock’s 50 day moving average is $2.33 and its 200-day moving average is $4.95.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets grew its stake in shares of Inovio Pharmaceuticals by 177.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 5,681 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 3,630 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Inovio Pharmaceuticals during the second quarter valued at about $82,000. SG Americas Securities LLC bought a new position in Inovio Pharmaceuticals during the third quarter worth about $71,000. MetLife Investment Management LLC increased its stake in shares of Inovio Pharmaceuticals by 129.1% in the third quarter. MetLife Investment Management LLC now owns 15,167 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 8,546 shares in the last quarter. Finally, Atom Investors LP bought a new stake in shares of Inovio Pharmaceuticals in the third quarter valued at approximately $103,000. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.